Navigation Links
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Date:5/8/2008

as given for only 24 percent of FLECTOR(R) Patch patients versus 34.4 percent of placebo patch patients (p<0.01).

Of the 418 patients randomized in the study, 49.3 percent were men and 99.5 percent were white. The mean age of the study participants was 38.9 years. The most common injuries reported were contusions (42.6 percent), strains (31.1 percent), and sprains (24.4 percent); the most common injury sites were ankle, shoulder, knee and foot (67.3 percent). Efficacy was evaluated in 384 (91.9 percent) patients (greater than or equal to one post- baseline pain assessment). Adverse events were similar between FLECTOR(R) Patch and placebo patch; the most common were application-site conditions, generally of mild severity (FLECTOR(R) Patch 7.9 percent, placebo patch 5.8 percent). The study was supported by a grant from Alpharma Pharmaceuticals LLC.

Comparison of Plasma Pharmacokinetics of FLECTOR(R) Patch and Oral Voltaren(R) in Healthy Volunteers (Abstract #8383/Poster #279)(3)

In order to compare the bioavailability of two formulations containing diclofenac, FLECTOR(R) Patch and Voltaren(R), a single-center, open-label, crossover study was conducted in 24 healthy volunteers. All study subjects received one FLECTOR(R) Patch every 12 hours for four consecutive days; 12 study subjects received a single 50-mg oral dose of Voltaren(R) in a two-way crossover fashion. Blood was collected at selected times post-dose to determine diclofenac plasma levels.

Results indicated that the systemic exposure to diclofenac with topical FLECTOR(R) Patch at a steady state (every 12 hours for four days) was approximately 1 percent of a single dose of Voltaren(R) (50-mg oral).

The study included an equal number of males and females, all Caucasian, with a mean age of 24.1 years. Subjects were required to have no skin disorders or abnormalities at the patch application site. Mean Cmax for FLECTOR(R) Patch (steady state) was 1.7 plus or minus 0.9ng/mL versu
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...cell AG (,Intercell,) to acquire Iomai Corporation...saction for USD 6.60 per share of Iomai,s common...f Iomai of approximately USD 189 million (EUR 12...h stock-for-stock exchange for approximately 41 pe...by major shareholders for,approximately 1.7 millio...
(Date:5/12/2008)...ORK, May 12 /PRNewswire-USNewswire/ -- The Allianc...its passage of a resolution,supporting the goals a...ins,annually on Mother,s Day. The resolution, intr...a Snowe (R-ME) calls on all Americans to take the,...ducate themselves on,women,s health issues, and re...
(Date:5/12/2008)...e cells adjust their function like a radio dial, n...at how autoimmune disease may develop,late in life.../ -- A St. Jude Children,s,Research Hospital study...lators, do not use simple on/off switches to gover...lopment and function. Rather, they,possess sophist...
(Date:5/12/2008)... show promising neurological recovery in severely-...atients treated with Cethrin, HOPKINTON, Mass., M...icals, Inc. (Nasdaq: ALSE ) today announced 12-mo...al of Cethrin, a proprietary recombinant,protein t...tore motor and,sensory function after spinal cord ...
Breaking Medicine Technology:Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5Campbell Alliance Business Development Practice Leader to Co Chair and Keynote at SRI Pharma Licensing Summit 7599 1Campbell Alliance Business Development Practice Leader to Co Chair and Keynote at SRI Pharma Licensing Summit 7599 2Campbell Alliance Business Development Practice Leader to Co Chair and Keynote at SRI Pharma Licensing Summit 7599 3HIV Collaborative Fund Receives Gates Foundation Grant for AIDS Treatment and Prevention Advocacy 7596 1HIV Collaborative Fund Receives Gates Foundation Grant for AIDS Treatment and Prevention Advocacy 7596 2HIV Collaborative Fund Receives Gates Foundation Grant for AIDS Treatment and Prevention Advocacy 7596 3Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 979 1Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 979 2Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 979 3Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 979 4Allergy Foundation Thinks Globally Gifts Locally 7592 1Allergy Foundation Thinks Globally Gifts Locally 7592 2
(Date:5/13/2008)...drew Raguskus to Serve as Senior Technology Adviso...-- The Board of Directors,of Sonic Innovations, In...d,digital hearing aids, today announced that Andre...rd. Mr. Raguskus will continue as a member of the,...ogy Advisor. As a result,of Mr. Raguskus, announce...
(Date:5/13/2008)...ealty Investment Trust invites Foundation to celeb...er life for people with CF,, BETHESDA, Md., Ma...kable progress in treating cystic fibrosis -- a fa...rust invited the Cystic Fibrosis Foundation,to joi...ock Exchange (NYSE),today., Life expectancy for...
(Date:5/13/2008)...ts as often as whites, researchers not sure why di...TUESDAY, May 13 (HealthDay News) -- Even though bl...referral rates to oncologists, blacks are less lik...new research shows. , In their study, researche...ancer Center looked at 2,582 white patients and 13...
(Date:5/13/2008)... helps prevent the disease, two additional studies...ay News) -- New research has found both bad news a...news is a risk factor you can,t change: Women whos...n increased risk of breast cancer throughout their...sis, according to a study in the May 13 issue of t...
Breaking Medicine News(10 mins):Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 2Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 3Health News:Cystic Fibrosis Foundation President Rings Bell to Close New York Stock Exchange 2Health News:Black Rectal Cancer Patients Less Likely to Get Chemo, Radiation 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3
...00 cell phone users were closely monitored by scie...Copenhagen to study //the harmful effects of cell ...sers of cell phones for over a decade. Few were us...It has been proven by scientists in previous studi...
...l unclear how the brain actually stores or deletes...icate functioning of the human brain,// feel that ...ation. This theory postulates that fresh impressio...a region of the brain called the hippocampus. Newl...
...xposed to chlorpyrifos-an insecticide, while in th...ental and motor development by three years of age ...s. This observation was made in a peer-reviewed st.... Chlorpyrifos, which was banned for residential...
...s feel that a second opinion is very vital for can...f treatment and it should surely be taken before u...omprehensive Cancer Center wanted to find out whet...ffered with specialists. The records of 149 breast...
Other Medicine News:Health News:Chlorpyrifos Affects Mental Development of Foetus 2Health News:Cancer? Get A Second Opinion 2
The Valleylab CUSA EXcel system is the recognized world leader, providing rapid, selective tissue fragmentation with superior tactile feedback and exceptional visualization of the operative site. Thi
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 7.5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard crankshaft-type 1/1 (mm), opening width 7.0 mm and length 5 mm.
Medicine Products: